Ceftaroline Is FDA Approved for Soft-Tissue Infections and Community-Acquired Pneumonia

Ceftaroline is the first FDA-approved cephalosporin with activity against MRSA.

On October 29, 2010, the FDA announced the approval of ceftaroline (Teflaro) for treatment of acute bacterial skin and soft-tissue infections (BSSTIs) — including those caused by methicillin-resistant Staphylococcus aureus (MRSA) — and community-acquired bacterial pneumonia (CABP) in adults aged ≥18.

Because it can bind to penicillin-binding protein 2a, ceftaroline is unique among FDA-approved cephalosporins in having good activity against MRSA. It also has good activity against streptococci, including Streptococcus pyogenes and multidrug-resistant Streptococcus pneumoniae; however, it lacks good activity against enterococci. Its gram-negative spectrum is more limited but includes CABP pathogens such as Haemophilus influenzae, Moraxella cata…

Author

Lynn L. Estes, PharmD

Disclosures

Editorial boardsMayo Clinic Antimicrobial Therapy Quick Guide

Lynn L. Estes, PharmD

Disclosures

Editorial boardsMayo Clinic Antimicrobial Therapy Quick Guide